SCHEMBL979744

SCHEMBL979744

CS(=O)(=O)N1CC=C(c2ccc(Br)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.49
TDO2 P48775 1/20 0.49
LMNA P02545 1/20 0.49
ALDH1A1 P00352 1/20 0.49
PKM P14618 1/20 0.49
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 1/20 0.47
RECQL P46063 1/20 0.47
KMT2A Q03164 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
CCNT1 O60563 10/20 0.45
CDK9 P50750 10/20 0.45
AURKA O14965 1/20 0.42
CDK1 P06493 1/20 0.42
NEK2 P51955 1/20 0.42
PLK1 P53350 1/20 0.42
NEK7 Q8TDX7 1/20 0.42
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11956930 0.87 LMNA (0.62) THRBTDO2LMNAALDH1A1PKM
SCHEMBL14320646 0.84 TDO2 (0.49) THRBTDO2LMNAALDH1A1PKM
SCHEMBL15615751 0.84 CCNT1 (0.49) THRBTDO2LMNAALDH1A1PKM
SCHEMBL979793 0.84 QDPR (0.58) THRBTDO2LMNAALDH1A1PKM
SCHEMBL6437476 0.83 MMP2 (0.49) THRBTDO2LMNAALDH1A1PKM
SCHEMBL1103889 0.81 CCNT1 (0.59) THRBTDO2LMNAALDH1A1PKM
SCHEMBL979985 0.80 WNT3A (0.46) THRBTDO2KDM4EMEN1RECQL
SCHEMBL979623 0.79 CCNT1 (0.49) THRBTDO2LMNAKDM4EMMP2
SCHEMBL24721518 0.77 MMP2 (0.56) THRBTDO2LMNAALDH1A1PKM
SCHEMBL26987050 0.77 TDO2 (0.43) THRBTDO2LMNAALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207344-B2 GPR119 agonists ELI LILLY AND COMPANY (US) 2012-06-26 US disclosed
US-8207344-B2 GPR119 agonists ELI LILLY AND COMPANY (US) 2012-06-26 US disclosed
EP-2454251-A1 GPR119 AGONISTS Eli Lilly and Company (US) 2012-05-23 EP disclosed
WO-2011008663-A1 GPR119 AGONISTS ELI LILLY AND COMPANY (US) 2011-01-20 WO disclosed
US-20110015199-A1 GPR119 Agonists ELI LILLY AND COMPANY (US) 2011-01-20 US disclosed
US-20110015199-A1 GPR119 Agonists ELI LILLY AND COMPANY (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015199-A1 GPR119 Agonists GPR119, GLP1R, GCGR THRB 227/4885TDO2 2500/4885LMNA 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.